Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · IEX Real-Time Price · USD
5.98
-0.17 (-2.76%)
At close: May 20, 2024, 4:00 PM
6.21
+0.23 (3.85%)
After-hours: May 20, 2024, 6:08 PM EDT

Company Description

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology.

The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases.

It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives.

The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021.

Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Nuvectis Pharma, Inc.
Nuvectis Pharma logo
Country United States
Founded 2020
IPO Date Feb 4, 2022
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Ron Bentsur M.B.A.

Contact Details

Address:
1 Bridge Plaza, Suite 275
Fort Lee, New Jersey 07024
United States
Phone 360-837-7232
Website nuvectis.com

Stock Details

Ticker Symbol NVCT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.00
CIK Code 0001875558
CUSIP Number 67080T108
ISIN Number US67080T1088
Employer ID 86-2405608
SIC Code 2834

Key Executives

Name Position
Ron Bentsur M.B.A. Co-Founder, Chairman, Chief Executive Officer and President
Dr. Enrique Poradosu Ph.D. Co-Founder, Executive Vice President, Chief Scientific and Business Officer
Shay Shemesh Co-Founder, Executive Vice President, Chief Development and Operations Officer
Michael Carson CPA Vice President of Finance

Latest SEC Filings

Date Type Title
May 7, 2024 10-Q Quarterly Report
May 7, 2024 8-K Current Report
Apr 29, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2024 DEF 14A Other definitive proxy statements
Mar 5, 2024 10-K Annual Report
Mar 5, 2024 8-K Current Report
Feb 28, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 6, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 1, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 1, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals